HER-2 positive + HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive + HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + ramucirumab Sensitive: C3 – Early Trials
|
trastuzumab + ramucirumab Sensitive: C3 – Early Trials
|
HER-2 positive + HER-2 amplification
|
Gastric Cancer
|
HER-2 positive + HER-2 amplification
|
Gastric Cancer
|
trastuzumab + ramucirumab Sensitive: C3 – Early Trials
|
trastuzumab + ramucirumab Sensitive: C3 – Early Trials
|
HER-2 positive + HER-2 amplification
|
Gastroesophageal Cancer
|
HER-2 positive + HER-2 amplification
|
Gastroesophageal Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|